you have symptoms of coronavirus (COVID-19) – a high temperature, a new continuous cough, or a loss of, or change in, your normal sense of smell or taste (anosmia) – the advice is to stay at home for 10 days. Information on self-isolation rules if a member of your household tests positive for Covid-19 or if you are classed as a contact, can be found here.

If you think you have symptoms, please do not attend your hospital appointment until you are advised it is safe to do so. Please contact us to rearrange your appointment, or to re-organise treatment and tests.

The latest information on the Covid-19 vaccination programme in Nottingham and Nottinghamshire can be found here

National centre for LAM

For guidance on shielding from COVID-19 please download the below document

For guidance on Coronavirus Vaccines and the National Centre for LAM please download the below document

Lymphangioleiomyomatosis (LAM) is a rare multi-system disease, which almost exclusively affects women. LAM can cause progressive loss of lung function, leading to breathlessness, lung collapse and lymphatic problems in the chest and abdomen.

The National Centre for Lymphangioleiomyomatosis (LAM) is a comprehensive clinical service for patients with LAM. It provides clinical care:

  • diagnostic workup of patients with suspected LAM
  • ongoing respiratory care either exclusively at the centre or in partnership with local providers
  • clinical and genetic evaluation of Tuberous Sclerosis Complex (TSC) in patients with LAM and evaluation of LAM in patients with TSC
  • evaluation and monitoring of renal angiomyolipoma
  • surgical assessment and treatment of complications
  • pre lung transplant evaluation and referral

In conjunction with the University of Nottingham, the LAM centre is also a hub for clinical trials of new therapies for LAM, evaluation of biomarkers, outcome and laboratory research into the molecular basis of the disease.